Hubbry Logo
AndrostaneAndrostaneMain
Open search
Androstane
Community hub
Androstane
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Androstane
Androstane
Androstane
View on Wikipedia
from Wikipedia
Androstane
Names
IUPAC name
5ξ-Androstane
Systematic IUPAC name
(3aS,3bS,5aΞ,9aS,9bS,11aS)-9a,11a-Dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene
Other names
Etioallocholane; 10β,13β-Dimethylgonane
Identifiers
3D model (JSmol)
ChEBI
ChemSpider
UNII
  • InChI=1S/C19H32/c1-18-11-5-7-16(18)15-9-8-14-6-3-4-12-19(14,2)17(15)10-13-18/h14-17H,3-13H2,1-2H3/t14?,15-,16-,17-,18-,19-/m0/s1 checkY
    Key: QZLYKIGBANMMBK-FZFXZXLVSA-N checkY
  • C[C@@]12[C@](CCC2)([H])[C@]3([H])CCC4([H])CCCC[C@]4(C)[C@@]3([H])CC1
  • C3C1CCCC[C@@]1([C@H]2CC[C@]4([C@H]([C@@H]2C3)CCC4)C)C
Properties
C19H32
Molar mass 260.465 g·mol−1
Density 0.95 g/ml
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Androstane is a C19 steroidal hydrocarbon with a gonane core. Androstane can exist as either of two isomers, known as 5α-androstane and 5β-androstane.

  • 5α-Androstane
    5α-Androstane
  • 5β-Androstane
    5β-Androstane

Pharmacology

[edit]

5α-Androstane is reported to be effective as an androgen, in spite of having no oxygen containing functional groups.[1][2]

Androstanes

[edit]

Androstanes are steroid derivatives with carbons present at positions 1 through 19.

See also: List of androstanes


See also

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Androstane

View on Grokipedia
from Grokipedia

Androstane is a saturated tetracyclic C19 with the molecular formula C19H32, serving as the fundamental parent structure for androstane-class steroids, including androgens. It features a gonane core with angular methyl groups at positions 10 and 13, distinguishing it from other steroid hydrocarbons like , which possess an additional side chain at C17. Androstane exists in two principal isomeric forms—5α-androstane and 5β-androstane—differing in the at the A/B ring junction, with the 5α form being more prevalent in mammalian biochemistry due to its association with 5α-reductase-mediated metabolites. As the skeletal framework for key endogenous androgens such as testosterone, dihydrotestosterone, and androsterone, androstane derivatives play critical roles in male sexual development, muscle anabolism, and metabolic regulation, underscoring their foundational importance in endocrinology and steroid hormone signaling. Synthetic modifications of the androstane nucleus have yielded anabolic-androgenic steroids used therapeutically for conditions like hypogonadism and cachexia, though they are also implicated in performance-enhancing doping due to their potent effects on protein synthesis and secondary sexual characteristics. The compound's saturated nature contrasts with unsaturated precursors like androstene, enabling diverse functionalization at positions such as C3 and C17 for biological activity.

Chemical Structure and Nomenclature

Core Framework

is a saturated C19H32 serving as the parent structure for the androstane series of , characterized by a tetracyclic . This core framework, derived from the gonane skeleton, features four linearly fused rings: three six-membered rings designated A, B, and C, and a five-membered ring D, with angular methyl groups attached at positions C10 (C19 methyl) and C13 (C18 methyl). The fusion between rings follows a trans configuration at most junctions, contributing to the rigid, planar nature of the molecule essential for steroid functionality. Standard steroid numbering begins at C1 in ring A, proceeding clockwise around the rings to C17 in ring D, with side chains or substituents typically at C17 for higher steroids, though androstane lacks an extended chain beyond C17. The systematic IUPAC name for the 5α-isomer is (8S,9S,10S,13S,14S)-10,13-dimethylhexadecahydro-1H-cyclopenta, reflecting the perhydrocyclopentanophenanthrene backbone with specified . In steroid , "androstane" denotes the fully saturated C19 parent, distinguishing it from unsaturated variants like androstene or oxygenated derivatives such as androstanediols. The core framework's at C5 defines the two primary isomers: 5α-androstane (with trans A/B fusion) and 5β-androstane (with cis A/B fusion), influencing molecular conformation and in derivatives. This structural rigidity and specific at eight asymmetric centers (C8, C9, C10, C13, C14, and potentially C5, C17) underpin the scaffold's role in androgenic and other hormones.

Isomers and Stereochemistry

Androstane possesses six chiral centers at carbons 5, 8, 9, 10, 13, and 14, enabling multiple stereoisomers, though the biologically relevant forms adhere to specific configurations. The principal distinction among androstane isomers lies in the at C5, yielding 5α-androstane and 5β-androstane. In 5α-androstane, the A/B ring fusion is trans, characterized by the α-orientation of the at C5 relative to the β-methyl group at C10, promoting a more extended conformation. Conversely, 5β-androstane exhibits a cis A/B fusion, with the at C5 in the β-position, resulting in a bent structure more typical of certain metabolites. Both isomers maintain trans fusions at the B/C and C/D junctions, with standard orientations including β-methyl groups at C10 and C13, and α-s at C9 and C14. The for 5α-androstane is designated as (5S,8R,9S,10S,13S,14S), reflecting the specific spatial arrangement derived from biosynthetic pathways. This influences metabolic processing, with 5α-androstane serving as a in pathways. Variations at other chiral centers, such as epi-isomers, occur but are less prevalent in natural contexts.

Physicochemical Properties

Physical Characteristics

5α-Androstane appears as a white to off-white crystalline solid. It has a of 50–51 °C and a of 336 °C at 760 mmHg. The density is predicted to be 0.95 g/cm³. As a non-polar , it shows low solubility in polar solvents like but is slightly soluble in at approximately 50 mg/mL. 5β-Androstane, the epi-isomer, is also a with a higher of 78–80 °C and a comparable of 336 °C at 760 mmHg. Its density is similarly around 0.95 g/cm³. Like its 5α counterpart, it exhibits hydrophobic character, with negligible in and preferential dissolution in non-polar organic solvents. Both isomers are lipophilic due to their fully saturated C19 framework, rendering them insoluble in aqueous media but compatible with apolar environments such as or . values around 1.508 have been reported for 5α-androstane.

Chemical Reactivity and Stability

Androstane, as a fully saturated C19 polycyclic , displays minimal chemical reactivity characteristic of alkanes, lacking sites for facile , substitution, or oxidation under ambient conditions. Its trans-fused ring system and angular methyl groups confer rigidity, limiting conformational flexibility that might otherwise expose reactive sites, though free-radical halogenation can occur preferentially at tertiary carbons (e.g., C-17 or methyl groups) under UV or high temperatures. Both 5α-androstane and 5β-androstane isomers are chemically stable, showing no tendency for , hazardous , or spontaneous reactions in air or moisture. They resist and mild oxidizing agents, with incompatibility primarily limited to strong oxidizers or reactive metals that could initiate or peroxidation at elevated temperatures above 300°C. In synthesis, the androstane core withstands acidic or basic conditions used for manipulations elsewhere in derivatives, underscoring its robustness as a scaffold.

Synthesis and Production

Biosynthetic Pathways

The of the , the C19 core structure of androgens, occurs primarily in the gonads and through steroidogenesis, starting from . is transported into mitochondria via the (StAR) and undergoes side-chain cleavage by the enzyme cytochrome P450 side-chain cleavage (CYP11A1) to form , the universal precursor for all steroids. This initial step requires NADPH and molecular oxygen and is rate-limiting, regulated by (ACTH) in adrenals and (LH) in gonads. Conversion to the androstane nucleus involves transformation of C21 intermediates to C19 steroids via 17,20-lyase activity, cleaving the C17-C20 bond to remove the two-carbon side chain. The bifunctional enzyme cytochrome P450 17α-hydroxylase/17,20-lyase () performs sequential 17α-hydroxylation followed by lyase action, with activity enhanced by cytochrome b5 in the of the . Two parallel pathways exist: the Δ5 pathway, yielding dehydroepiandrosterone (DHEA) from 17α-hydroxypregnenolone, and the Δ4 pathway, yielding from (itself from progesterone via 3β-hydroxysteroid dehydrogenase type 2, HSD3B2). These C19 Δ4-3-keto steroids represent the foundational androstane framework before further saturation or functionalization. Subsequent transformations produce active androgens bearing the androstane skeleton. Androstenedione is reduced to testosterone by 17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3, encoded by HSD17B3) in the testes, while DHEA is isomerized to via HSD3B enzymes. Testosterone is then 5α-reduced to the more potent (DHT) by types 1 and 2 (SRD5A1/2), saturating the Δ4 bond to form the canonical 5α-androstane structure. In peripheral tissues like and adipose, metabolism activates circulating DHEA and locally via these enzymes, bypassing gonadal testosterone. An alternative "backdoor" pathway generates DHT directly from progesterone or without passing through testosterone, involving early 5α-reduction (SRD5A), oxidation to 17α-hydroxy dihydroprogesterone, and -mediated cleavage to , followed by oxidation to DHT via aldo-keto reductase 1C (AKR1C) enzymes. This route predominates in fetal development and certain pathologies like , contributing up to 20-40% of DHT in some contexts. Adrenal production favors weak androgens like DHEA (sulfated to DHEAS for circulation) and 11-oxygenated derivatives (e.g., 11-ketotestosterone via CYP11B1), reflecting zona reticularis expression of but limited HSD3B2.

Chemical Synthesis Methods

Androstane, the saturated C19 hydrocarbon, is primarily synthesized through partial reduction of naturally derived or semi-synthetic oxygenated precursors rather than de novo , due to the complexity and inefficiency of constructing the tetracyclic core from simple starting materials. A common preparative route involves catalytic of Δ5-unsaturated androstane derivatives, such as 3β-hydroxy-5-androsten-17-one, using or catalysts under acidic conditions to selectively yield the 5α-epimer. This stereoselective reduction exploits the thermodynamic preference for the 5α-configuration in androstane systems, with reaction conditions typically involving or acetic acid solvents at and , achieving high yields of the saturated 5α-androstane skeleton after subsequent . Deoxygenation of functional groups in intermediates like androstan-3,17-dione or is accomplished via reductive methods such as Wolff-Kishner or , converting carbonyl moieties to methylene groups while preserving the ring fusions. For instance, androstan-17-ols are subjected to hydrogenolysis or tosylate formation followed by reduction to remove hydroxy groups, yielding the parent hydrocarbon. These methods leverage commercially available precursors like dehydroepiandrosterone, enabling scalable production for research, though they inherit from the natural source material. Total syntheses of androstane, though less practical for bulk preparation, demonstrate the feasibility of assembling the skeleton from acyclic precursors and have advanced stereocontrol techniques. A notable 1979 route employs an SnCl₄-catalyzed Diels-Alder to forge ring C, establishing the β-methyl at C13 and H at C8 with high diastereoselectivity, followed by keto ester cyclization to complete the tetracycle. Subsequent reductions and adjustments yield androstane derivatives. Alternative total approaches, such as those for (±)-androstane-2,17-dione, utilize intramolecular Diels-Alder reactions or metal-involved annulations to build rings A/B and D sequentially, highlighting the challenges in achieving the trans-anti-trans-anti-trans fusion. These racemic syntheses, reported in the mid-20th century onward, prioritize proof-of-concept over enantiopurity, as or asymmetric variants remain underdeveloped for the unsubstituted .

Biological Significance

Role as Androgen Precursor

Androstane constitutes the core tetracyclic hydrocarbon skeleton (C19H32) underlying all steroids, which exert primary masculinizing effects through binding to the . In steroidogenesis, this skeleton emerges via enzymatic side-chain cleavage of C21 precursors, such as progesterone or , primarily in the Leydig cells of the testes, cells of the ovaries, and zona reticularis of the . The process begins with conversion to by CYP11A1, followed by sequential hydroxylations and lyase actions (e.g., CYP17A1-mediated 17,20-lyase activity), yielding C19 intermediates like dehydroepiandrosterone (DHEA) and that retain the androstane framework. These androstane-derived precursors possess weak intrinsic androgenic activity but serve as substrates for conversion to potent androgens. , for instance, is reduced to testosterone by 17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3) in the gonads, accounting for the majority of circulating testosterone in males (approximately 95% from testicular synthesis). DHEA, secreted abundantly by the adrenals (up to 25 mg/day in young adults), undergoes peripheral transformation via 3β-HSD and 17β-HSD enzymes to and testosterone, contributing 5-10% to total androgens in men and a larger fraction in women. In target tissues like and , testosterone is irreversibly reduced to (DHT) by isoforms (types 1 and 2), yielding a 5α-androstane derivative with 2-10 times greater potency due to higher receptor affinity and slower dissociation. Alternative "backdoor" pathways bypass testosterone, directly generating DHT from 5α-reduced androstane intermediates such as 5α-androstane-3α,17β-diol or , particularly in conditions like or castration-resistant where classic routes are impaired. These pathways, involving enzymes like 3α-HSD and 17β-HSD5, highlight androstane's versatility as a scaffold for production independent of the Δ4-androstenedione bottleneck, with evidence from isotopic tracer studies showing up to 20-40% of DHT deriving from backdoor routes in fetal development and certain pathologies. Adrenal C19 steroids thus provide a reservoir for extra-gonadal synthesis, influencing pubertal , muscle , and , though dysregulation elevates risks like .

Endogenous Metabolism and Derivatives

In human physiology, endogenous androstane derivatives primarily arise from the 5α-reduction of testosterone and androstenedione, catalyzed by steroid 5α-reductase isoenzymes (SRD5A1 and SRD5A2), which saturate the Δ4-5 double bond in the A-ring to form the 5α-androstane nucleus. This irreversible step occurs predominantly in androgen target tissues such as prostate, skin, and liver, with SRD5A2 predominating in genital tissues and SRD5A1 in nongenital sites like sebaceous glands. The resulting 5α-dihydrotestosterone (DHT; 5α-androstan-17β-ol-3-one) is a more potent androgen than testosterone, amplifying androgen receptor signaling before undergoing further inactivation. Subsequent metabolism of DHT involves oxidation at the 17β-position by 17β-hydroxysteroid dehydrogenases (17β-HSDs), yielding 5α-androstane-3,17-dione, followed by reduction at the 3-keto group by 3α-hydroxysteroid dehydrogenases (3α-HSDs) to produce (5α-androstan-3α-ol-17-one). Alternatively, DHT can be reduced directly at the 3-keto group to 5α-androstane-3α,17β-diol (3α-diol), a weaker of the that serves as a precursor to via 17β-HSD activity. These transformations represent inactivation pathways, with and its 3β-epimer epiandrosterone excreted primarily in urine as or conjugates after hepatic processing. A minor 5β-reduction pathway, mediated by less specific reductases, generates 5β-androstane derivatives such as etiocholanolone (5β-androstan-3α-ol-17-one) from testosterone or androstenedione, though this route contributes only about 20-30% of total 17-ketosteroid excretion in adult males compared to the 5α-pathway. Etiocholanolone lacks significant androgenic activity and is rapidly conjugated for elimination, reflecting its role in androgen catabolism rather than signaling. Additionally, a "backdoor" pathway bypasses testosterone, converting progesterone derivatives to androsterone as an intermediate en route to DHT, particularly active in fetal development and certain tissues. These metabolites collectively account for over 40% of daily turnover in humans, with urinary 17-ketosteroids like and etiocholanolone serving as biomarkers of production; daily excretion rates average 1-3 mg for and 2-5 mg for etiocholanolone in adult males. Enzymatic deficiencies, such as in type 2, disrupt this , leading to elevated testosterone-to-DHT ratios and conditions like 5α-reductase deficiency syndrome.

Derivatives and Applications

Natural Androstanes

Natural androstanes comprise endogenous steroids featuring the saturated C19 androstane nucleus, formed predominantly through the peripheral of like and in mammals, including humans. These compounds arise via reductase enzymes that saturate the Δ4-ene bond and modify functional groups at C3 and C17, yielding primarily 17-ketosteroids excreted in urine as biomarkers of androgen turnover. The principal natural androstane is (5α-androstan-3α-ol-17-one), generated from through 3α-reduction followed by 17-oxidation, or alternatively from androstanedione via 3α-reduction; this pathway predominates in tissues expressing type II, such as and . possesses weak androgenic potency but functions as a , modulating and GABA_A receptors to influence neuronal excitability. Etiocholanolone (5β-androstan-3α-ol-17-one), the 5β-isomer, emerges via parallel 5β-reduction of testosterone or , primarily in hepatic tissues, and constitutes a major urinary etiocholanone alongside , with daily excretion varying by sex and age but typically comprising 1-3 mg in adult males. Like , it exhibits modest , including pyrogenic effects upon injection, historically exploited to assess marrow function.
CompoundSystematic NameBiosynthetic OriginKey Biological Role
Androsterone3α-Hydroxy-5α-androstan-17-oneMetabolite of DHT and androstanedioneNeurosteroid, weak androgen, urinary excretion
Etiocholanolone3α-Hydroxy-5β-androstan-17-oneMetabolite of testosterone via 5β-pathwayUrinary metabolite, immunostimulant
Androstanedione5α-Androstane-3,17-dioneIntermediate in 5α-androgen reductionPrecursor to androsterone
Additional minor natural androstanes, such as 3α,5α-androstanediol, occur as transient intermediates in these reductive cascades, contributing to local inactivation. While primarily endogenous, traces appear in select plant materials like pine pollen, underscoring limited phytosteroid parallels to animal metabolism.

Synthetic Androstane Derivatives

Synthetic androstane derivatives are chemically engineered steroids built upon the C19 androstane nucleus, designed to amplify anabolic effects—such as protein synthesis and retention—while modulating androgenic activity, , and receptor selectivity compared to endogenous androgens like testosterone. These compounds emerged from systematic structural modifications starting in following the isolation of testosterone in , with early efforts focused on enhancing therapeutic utility for conditions including , , and . Key innovations included 17α-alkylation to enable by evading first-pass hepatic degradation, and 19-demethylation to reduce estrogenic side effects via impaired . Over 100 such derivatives have been synthesized, though only a subset gained clinical approval due to efficacy-risk balances informed by empirical trials showing dose-dependent gains in but elevated risks of and cardiovascular strain. Prominent examples include , a 19-norandrostane (specifically 17β-hydroxyestr-4-en-3-one) first synthesized in 1950 and approved for medical use in 1959, which exhibits approximately 3-4 times the anabolic potency of testosterone with diminished androgenic effects, as measured by muscle assays in rodents. , a 17α-methylated analog developed in the 1950s, promotes in anemic patients via stimulation of activity, with clinical data from 1960s trials demonstrating increases of 2-3 g/dL after 4-6 weeks at 50 mg/day doses. , featuring a ring fused at C2-C3 and synthesized in 1959, offers high oral bioavailability and has been used for , though long-term studies highlight risks like .
CompoundKey ModificationAnabolic:Androgenic Ratio (approx., via Hershberger assay)Approved Indications (examples)
19-Demethylation, Δ4-unsaturation10:1,
17α-Methyl, 2-hydroxymethylene3:1
17α-Methyl, pyrazoline fusion3:1, growth failure
Beyond AAS, specialized synthetic derivatives target niche pathways; for instance, trilostane analogs inhibit , reducing synthesis in treatment, with phase II trials in the confirming adrenal suppression at 240-480 mg/day. Recent syntheses explore antiproliferative agents, such as A,B-modified D-homo androstanes, which inhibit tumor cell lines like via disruption, though human efficacy remains preclinical. These modifications underscore causal links between , receptor binding affinity (e.g., Kd values 0.1-10 nM for AR), and outcomes, validated through structure-activity relationship studies rather than anecdotal reports. Empirical data from randomized controlled trials emphasize benefits in catabolic states but caution against non-medical use, where supraphysiological doses (e.g., >600 mg/week) correlate with 2-5 fold increased rates.

Pharmacological Uses and Effects

Synthetic derivatives of androstane, classified as anabolic-androgenic steroids (AAS), are utilized in for their capacity to activate receptors, thereby enhancing protein synthesis, retention, and cellular growth in muscle and tissues. These effects stem from their structural similarity to testosterone, the primary endogenous , allowing them to promote anabolic processes while also eliciting androgenic responses such as . Clinically, AAS based on the androstane nucleus, including testosterone esters and , demonstrate efficacy in counteracting catabolic states by increasing and physical strength, as evidenced by controlled studies measuring improvements in metrics. A primary therapeutic application involves for syndromes, such as primary or secondary in males, where administration of androstane-derived testosterone restores serum levels to physiological ranges (typically 300-1000 ng/dL), mitigating symptoms including reduced muscle mass, risk, and impairment. In postmenopausal women with , certain AAS like exhibit palliative effects by inhibiting tumor growth through agonism, though usage has declined with alternative therapies. Additionally, , a 19-norandrostane , is employed to treat in patients by stimulating production, with clinical data showing increases of 1-2 g/dL after 3-6 months of therapy. In conditions of severe , such as those associated with or advanced cancer, short-term AAS regimens have yielded empirical gains in weight and functional status; for instance, , a dihydroandrostane , improved body weight by an average of 2-4 kg in randomized trials involving cachectic patients unresponsive to nutritional support alone. Veterinary extends these uses to promote growth in and recovery in performance animals, leveraging dose-dependent anabolic effects documented in metabolic studies. Pharmacodynamically, these compounds exhibit tissue-selective potency, with modifications to the androstane core (e.g., 17α-alkylation) altering and reducing hepatic first-pass metabolism, though this often correlates with elevated risks in prolonged use.

Controversies and Societal Impact

Medical Benefits and Empirical Evidence

Androstane derivatives, notably testosterone and synthetic analogs such as and , serve as the basis for (ART) primarily in treating male hypogonadism, a condition characterized by deficient testosterone production leading to symptoms like fatigue, reduced , and muscle loss. Clinical trials demonstrate that testosterone therapy significantly enhances in hypogonadal men, including improvements in , erectile function, and sexual satisfaction, with meta-analyses reporting effect sizes sufficient to alleviate these core symptoms. For instance, a 2018 guideline, informed by systematic reviews, confirms that ART increases and activity based on randomized controlled trials (RCTs) involving over 1,000 participants. Beyond sexual health, empirical evidence supports modest gains in and physical function. RCTs, including those pooling data from multiple studies, show testosterone increases by 1-2 kg and reduces fat mass, particularly in middle-aged and older men with confirmed low testosterone levels (<300 ng/dL). These changes correlate with enhanced muscle strength and stair-climbing power, as measured in placebo-controlled trials like the Testosterone in Older Men with Mobility Limitations (TOM) study, though benefits are more pronounced in those with baseline frailty. density at the spine and hip also improves by approximately 3-5% over 1-2 years of treatment, reducing risk in hypogonadal populations, per longitudinal cohort data and RCTs. Quality-of-life metrics, including mood and levels, exhibit variable but positive responses, with meta-analyses indicating small to moderate improvements in depressive symptoms and overall scores on validated scales like the Aging Males' Symptoms . A 2020 systematic review of 23 RCTs found ART superior to for and mood in hypogonadal men, though effects diminish if serum testosterone remains suboptimally elevated. In women, limited evidence from smaller trials suggests androstane-derived androgens (e.g., testosterone patches) may alleviate associated with or , with RCTs reporting doubled satisfactory sexual events per month versus . However, these benefits lack the robustness of male data, with calls for larger trials to confirm long-term . Certain synthetic androstane derivatives, like , show targeted benefits in catabolic states such as burn injuries or HIV-associated wasting, where RCTs demonstrate accelerated and weight gain of 2-4 kg over 12 weeks compared to standard care. Overall, while benefits are empirically supported for symptom relief in diagnosed deficiency states, they are dose- and duration-dependent, with no strong for healthy individuals or enhancement outside therapeutic contexts.

Risks, Side Effects, and Criticisms

Anabolic-androgenic steroids (AAS), synthetic derivatives of the androstane skeleton, are associated with a range of adverse health effects, particularly when misused at supraphysiological doses for performance enhancement. These include cardiovascular complications such as , , increased risk, arrhythmias, and sudden cardiac death, with mechanisms involving pro-arrhythmic effects and . Hepatic , including and , is prominent with oral 17α-alkylated androstane derivatives like methyltestosterone, though less common with injectable forms. Reproductive and endocrine disruptions are well-documented, encompassing gonadal axis suppression leading to , , , and reduced endogenous testosterone production, often persisting post-discontinuation. In females, virilization effects such as , voice deepening, and menstrual irregularities occur due to excess. Dermatological issues like acne vulgaris and accelerated , alongside erythrocytosis increasing risk, further compound physiological burdens. Psychiatric side effects include heightened ("roid rage"), mood disorders, anxiety, depression, and , potentially mediated by and hormonal dysregulation. Long-term abuse correlates with elevated all-cause mortality, including twofold increased cardiovascular death rates, underscoring dose- and duration-dependent risks. Criticisms of androstane derivative use center on their non-medical promotion in fitness communities despite of multisystem , with unregulated supplements like showing carcinogenic potential in rodent models and exacerbating estrogen-related imbalances. Observational data highlight underreporting of adverse events due to illicit sourcing and self-administration, complicating , while some advocate for stricter given persistent in up to 20% of former users. Proponents of therapeutic use argue risks are mitigated under supervision, yet critics note insufficient longitudinal trials to fully quantify rare events like prostate .

Regulatory and Ethical Debates

Anabolic-androgenic steroids (AAS), derivatives of the androstane nucleus, are classified as Schedule III controlled substances under the U.S. following the Anabolic Steroid Control Act of 1990, which criminalized non-medical possession and distribution with penalties including up to one year imprisonment for first offenses. This legislation was amended by the Anabolic Steroid Control Act of 2004, effective January 20, 2005, expanding the definition to encompass approximately 60 additional designer steroids and prohormones like , mandating research into detection methods and education programs to curb abuse. Similar restrictions apply internationally, with AAS designated as controlled substances in countries including , , , and the (Class C under the Misuse of Drugs Act), prohibiting non-prescribed use due to recognized potential for abuse despite accepted medical applications such as treating . In sports, the (WADA) prohibits AAS and related androstane derivatives in both in-competition and out-of-competition periods under the category of anabolic agents, as outlined in the annual Prohibited List updated effective January 1 each year, with violations leading to sanctions like two-to-four-year bans depending on intent and evidence. This framework, enforced through the World Anti-Doping Code, aims to preserve the "spirit of sport" by ensuring fair competition, though enforcement relies on testing protocols that detect metabolites of substances like 19-norandrostenedione, which remain banned despite some natural endogenous production. Ethical debates center on the tension between therapeutic legitimacy and non-medical enhancement, with proponents of stricter regulations arguing that AAS undermine fairness in athletics by providing unnatural advantages, potentially eroding in competition outcomes, as evidenced by high-profile doping scandals. Critics, however, contend that outright prohibitions for competent adults infringe on personal autonomy, given of efficacy in and strength gains when used responsibly, and question the consistency of bans when compared to tolerated enhancements like advanced or . Physicians face dilemmas in prescribing for legitimate indications versus enabling abuse, with calls for approaches like monitored therapy to mitigate risks such as dependence—affecting up to 30% of users—rather than punitive measures that drive underground markets. These discussions highlight causal trade-offs: while regulations curb widespread doping, they may overlook evidence-based medical benefits and exacerbate black-market dangers from products.

References

  1. https://pubchem.ncbi.nlm.nih.gov/compound/Androstane
  2. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/androstane
  3. https://www.tabers.com/tabersonline/view/Tabers-Dictionary/762775/all/androstane
  4. https://www.sciencedirect.com/topics/nursing-and-health-professions/androstane-derivative
  5. https://webbook.nist.gov/cgi/cbook.cgi?ID=C24887750&Mask=200
  6. https://webbook.nist.gov/cgi/cbook.cgi?ID=C24887750
  7. https://pubchem.ncbi.nlm.nih.gov/compound/94144
  8. https://pubchem.ncbi.nlm.nih.gov/compound/6857462
  9. https://www.pharmacy180.com/article/steroid-nomenclature-and-structure-2339/
  10. https://www.mdpi.com/2673-8015/4/3/25
  11. https://www.researchgate.net/figure/Stereoisomers-of-androstane-The-stereo-layer-in-the-InChIs-is-highlighted-a-5-a_fig4_6018774
  12. https://www.sigmaaldrich.com/US/en/product/sigma/a0887
  13. https://www.guidechem.com/dictionary/en/438-22-2.html
  14. https://www.chemicalbook.com/ProductChemicalPropertiesCB5698956_EN.htm
  15. https://www.chemsrc.com/en/cas/438-23-3_685772.html
  16. https://www2.chemistry.msu.edu/faculty/reusch/virttxtjml/funcrx1.htm
  17. https://chem.libretexts.org/Courses/Sacramento_City_College/SCC%253A_Chem_420_-_Organic_Chemistry_I/04%253A_Structure_and_Stereochemistry_of_Alkanes
  18. https://datasheets.scbt.com/sc-239083.pdf
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC6857441/
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC9991025/
  21. https://www.sciencedirect.com/science/article/abs/pii/0039128X84900187
  22. https://pubmed.ncbi.nlm.nih.gov/6523554/
  23. https://pubs.acs.org/doi/10.1021/jo01077a622
  24. https://pubs.rsc.org/en/content/articlelanding/1979/c3/c39790000028
  25. https://cdnsciencepub.com/doi/10.1139/v79-549
  26. https://pubs.acs.org/doi/10.1021/jo00149a006
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC4437668/
  28. https://www.sciencedirect.com/science/article/pii/S1521690X22000525
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC9569951/
  30. https://www.nature.com/articles/srep32198
  31. https://e-apem.org/m/journal/view.php?number=936
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC1472916/
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC9260366/
  34. https://joe.bioscientifica.com/view/journals/joe/57/1/joe_57_1_011.xml
  35. https://www.sciencedirect.com/topics/medicine-and-dentistry/etiocholanolone
  36. https://www.ncbi.nlm.nih.gov/books/NBK539904/
  37. https://www.ncbi.nlm.nih.gov/books/NBK279000/
  38. https://www.hmdb.ca/metabolites/HMDB0000490
  39. https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2020.00044/full
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC7098970/
  41. https://pubmed.ncbi.nlm.nih.gov/3857915/
  42. https://www.sciencedirect.com/topics/neuroscience/androstanedione
  43. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.1059473/full
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC4462045/
  45. https://www.sciencedirect.com/science/article/abs/pii/S0149291801801144
  46. https://www.clinicaltherapeutics.com/article/S0149-2918%2801%2980070-9/references
  47. https://www.sciencedirect.com/science/article/abs/pii/S0149763403000642
  48. https://www.sciencedirect.com/topics/neuroscience/androstane-derivative
  49. https://pubs.rsc.org/en/content/articlelanding/2013/ra/c3ra41336e
  50. https://www.ncbi.nlm.nih.gov/books/NBK482418/
  51. https://pubmed.ncbi.nlm.nih.gov/11589254/
  52. https://my.clevelandclinic.org/health/treatments/5521-anabolic-steroids
  53. https://academic.oup.com/jcem/article/103/5/1745/4939466
  54. https://academic.oup.com/jcem/article/103/5/1715/4939465
  55. https://www.aafp.org/pubs/afp/issues/2017/1001/p441.html
  56. https://www.acpjournals.org/doi/10.7326/M19-0830
  57. https://pubmed.ncbi.nlm.nih.gov/16822626/
  58. https://www.nejm.org/doi/full/10.1056/NEJMra2404637
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC7832337/
  60. https://nyaspubs.onlinelibrary.wiley.com/doi/full/10.1111/nyas.15187
  61. https://academic.oup.com/jcem/article/104/7/2490/5310131
  62. https://www.mdpi.com/2673-6756/5/3/31
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC8683244/
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC3148326/
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC8539210/
  66. https://www.sciencedirect.com/science/article/abs/pii/S027323001000019X
  67. https://www.govinfo.gov/link/plaw/108/public/358
  68. https://www.federalregister.gov/documents/2005/12/16/05-23907/implementation-of-the-anabolic-steroid-control-act-of-2004
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC10759908/
  70. https://www.wada-ama.org/sites/default/files/2023-09/2024list_en_final_22_september_2023.pdf
  71. https://www.wada-ama.org/en/prohibited-list
  72. https://journalofethics.ama-assn.org/article/steroid-hysteria-unpacking-claims/2005-11
  73. https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-019-0343-1
  74. https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-022-13734-4
Add your contribution
Related Hubs
User Avatar
No comments yet.